

World Journal of *Gastroenterology*

World J Gastroenterol 2024 March 21; 30(11): 1470-1643



EDITORIAL

- 1470 MicroRNAs in hepatocellular carcinoma treatment: Charting the path forward
Lin HT, Castaneda AFA, Krishna SG, Mumtaz K
- 1475 Innovative pathways allow safe discharge of mild acute pancreatitis from the emergency room
Kothari DJ, Sheth SG
- 1480 Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
Brilakis L, Theofilogiannakou E, Lykoudis PM
- 1488 Routine utilization of machine perfusion in liver transplantation: Ready for prime time?
Parente A, Sun K, Dutkowski P, Shapiro AJ, Schlegel A
- 1494 Advancements in Barrett's esophagus detection: The role of artificial intelligence and its implications
Massironi S

REVIEW

- 1497 MicroRNAs: A novel signature in the metastasis of esophageal squamous cell carcinoma
Wei QY, Jin F, Wang ZY, Li BJ, Cao WB, Sun ZY, Mo SJ

MINIREVIEWS

- 1524 Morphological and biochemical characteristics associated with autophagy in gastrointestinal diseases
Chang YF, Li JJ, Liu T, Wei CQ, Ma LW, Nikolenko VN, Chang WL

ORIGINAL ARTICLE

Retrospective Study

- 1533 Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors
Yang LM, Wang HJ, Li SL, Gan GH, Deng WW, Chang YS, Zhang LF

Clinical Trials Study

- 1545 Effect of *Aspergillus niger* prolyl endopeptidase in patients with celiac disease on a long-term gluten-free diet
Stefanolo JP, Segura V, Grizzuti M, Heredia A, Comino I, Costa AF, Puebla R, Temprano MP, Niveloni SI, de Diego G, Oregui ME, Smecuol EG, de Marzi MC, Verdú EF, Sousa C, Bai JC
- 1556 Effects of *Lactobacillus paracasei* N1115 on gut microbial imbalance and liver function in patients with hepatitis B-related cirrhosis
Hu YC, Ding XC, Liu HJ, Ma WL, Feng XY, Ma LN

Prospective Study

- 1572** Washed microbiota transplantation for Crohn's disease: A metagenomic, metatranscriptomic, and metabolomic-based study

Chen SJ, Zhang DY, Wu X, Zhang FM, Cui BT, Huang YH, Zhang ZL, Wang R, Bai FH

Basic Study

- 1588** Silent information regulator sirtuin 1 ameliorates acute liver failure *via* the p53/glutathione peroxidase 4/gasdermin D axis

Zhou XN, Zhang Q, Peng H, Qin YJ, Liu YH, Wang L, Cheng ML, Luo XH, Li H

- 1609** Identification of an immune-related gene signature for predicting prognosis and immunotherapy efficacy in liver cancer *via* cell-cell communication

Li JT, Zhang HM, Wang W, Wei DQ

META-ANALYSIS

- 1621** Effects of neoadjuvant chemotherapy *vs* chemoradiotherapy in the treatment of esophageal adenocarcinoma: A systematic review and meta-analysis

Csontos A, Fazekas A, Szakó L, Farkas N, Papp C, Ferenczi S, Bellyei S, Hegyi P, Papp A

CASE REPORT

- 1636** Myocardial metastasis from ZEB1- and TWIST-positive spindle cell carcinoma of the esophagus: A case report

Shibata Y, Ohmura H, Komatsu K, Sagara K, Matsuyama A, Nakano R, Baba E

ABOUT COVER

Editorial Board of *World Journal of Gastroenterology*, David L Morris, MD, FRCS (Ed), Professor, Department of Surgery, University of New South Wales, Sydney 2217, New South Wales, Australia. david.morris@unsw.edu.au

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE), MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJG as 4.3; Quartile category: Q2. The WJG's CiteScore for 2021 is 8.3.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Yi-Xuan Cai; Production Department Director: Xu Guo; Cover Editor: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EXECUTIVE ASSOCIATE EDITORS-IN-CHIEF

Xian-Jun Yu (Pancreatic Oncology), Jian-Gao Fan (Chronic Liver Disease), Hou-Bao Liu (Biliary Tract Disease)

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

March 21, 2024

COPYRIGHT

© 2024 Baishideng Publishing Group Inc

PUBLISHING PARTNER

Shanghai Pancreatic Cancer Institute and Pancreatic Cancer Institute, Fudan University
Biliary Tract Disease Institute, Fudan University

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/gerinfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/gerinfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

POLICY OF CO-AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/310>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/gerinfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>

PUBLISHING PARTNER's OFFICIAL WEBSITE

<https://www.shca.org.cn>
<https://www.zs-hospital.sh.cn>



Clinical Trials Study

Effects of *Lactobacillus paracasei* N1115 on gut microbial imbalance and liver function in patients with hepatitis B-related cirrhosis

Yan-Chao Hu, Xiang-Chun Ding, Hui-Juan Liu, Wan-Long Ma, Xue-Yan Feng, Li-Na Ma

Specialty type: Gastroenterology and hepatology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Wierzbicka A, Poland

Received: December 17, 2023

Peer-review started: December 17, 2023

First decision: December 25, 2023

Revised: January 8, 2024

Accepted: March 4, 2024

Article in press: March 4, 2024

Published online: March 21, 2024



Yan-Chao Hu, Xiang-Chun Ding, Hui-Juan Liu, Wan-Long Ma, Xue-Yan Feng, Li-Na Ma, Department of Infectious Disease, General Hospital of Ningxia Medical University, Yinchuan 750004, Ningxia Hui Autonomous Region, China

Xiang-Chun Ding, Infectious Disease Clinical Research Center of Ningxia, Yinchuan 750004, Ningxia Hui Autonomous Region, China

Corresponding author: Xiang-Chun Ding, MD, Doctor, Department of Infectious Disease, General Hospital of Ningxia Medical University, No. 804 Shengli Street, Yinchuan 750004, Ningxia Hui Autonomous Region, China. 13619511768@163.com

Abstract

BACKGROUND

Hepatitis B cirrhosis (HBC) is a chronic disease characterized by irreversible diffuse liver damage and aggravated by intestinal microbial imbalance and metabolic dysfunction. Although the relationship between certain single probiotics and HBC has been explored, the impact of the complex ready-to-eat *Lactobacillus paracasei* N1115 (LP N1115) supplement on patients with HBC has not been determined.

AIM

To compare the changes in the microbiota, inflammatory factor levels, and liver function before and after probiotic treatment in HBC patients.

METHODS

This study included 160 HBC patients diagnosed at the General Hospital of Ningxia Medical University between October 2018 and December 2020. Patients were randomly divided into an intervention group that received LP N1115 supplementation and routine treatment and a control group that received routine treatment only. Fecal samples were collected at the onset and conclusion of the 12-wk intervention period. The structure of the intestinal microbiota and the levels of serological indicators, such as liver function and inflammatory factors, were assessed.

RESULTS

Following LP N1115 intervention, the intestinal microbial diversity significantly increased in the intervention group ($P < 0.05$), and the structure of the intestinal microbiota was characterized by an increase in the proportions of probiotic

microbes and a reduction in harmful bacteria. Additionally, the intervention group demonstrated notable improvements in liver function indices and significantly lower levels of inflammatory factors ($P < 0.05$).

CONCLUSION

LP N1115 is a promising treatment for ameliorating intestinal microbial imbalance in HBC patients by modulating the structure of the intestinal microbiota, improving liver function, and reducing inflammatory factor levels.

Key Words: Hepatitis B cirrhosis; N1115 ready-to-eat lactobacillus; Inflammation; Liver function; Lachnospiraceae incertae sedis; Probiotic

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Intestinal microbial imbalance and metabolic dysfunction may accelerate the process of liver cirrhosis. We explored the role of probiotic intervention in patients with hepatitis B cirrhosis in this study. After an intervention with the N1115 ready-to-eat *Lactobacillus* supplement, we found the following significant changes: an increase in gut microbial diversity, structural changes in the microbiota favoring the growth of probiotic microbes, improvements in liver function, and decreases in inflammatory factor levels. We conclude that supplementation with the N1115 ready-to-eat *Lactobacillus* product may be a beneficial intervention in patients with cirrhosis.

Citation: Hu YC, Ding XC, Liu HJ, Ma WL, Feng XY, Ma LN. Effects of *Lactobacillus paracasei* N1115 on gut microbial imbalance and liver function in patients with hepatitis B-related cirrhosis. *World J Gastroenterol* 2024; 30(11): 1556-1571

URL: <https://www.wjgnet.com/1007-9327/full/v30/i11/1556.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v30.i11.1556>

INTRODUCTION

Liver cirrhosis (LC) is a severe chronic liver disease characterized by extensive hepatocyte degeneration, fibrosis, and nodular regeneration caused by various factors[1]. In China, 85% of cirrhosis and hepatocellular carcinoma (HCC) cases are attributed to hepatitis B virus (HBV) infection[2]. Approximately 257 million people are infected with HBV annually worldwide, leading to approximately 887000 deaths annually, approximately 30% of which result from LC[2]. Decompensated hepatitis B cirrhosis (HBC) often leads to multiple-organ dysfunction, such as gastrointestinal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis (SBP), primary liver cancer (PLC), and hepatorenal syndrome, often necessitating liver transplantation for survival[3].

Patients with LC often experience varying degrees of intestinal flora imbalance. The intestinal microbiota not only directly affects intestinal health but also influences liver metabolism and immunity. The gut microbiota plays a critical role in the development of various chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), LC, and PLC. Alterations in the gut microbiota can lead to immune dysregulation, intestinal barrier dysfunction, and systemic inflammation through the gut-liver axis, thus promoting disease progression. The gut microbiota is closely associated with LC complications and liver disease[4-11]. Given the growing understanding of intestinal flora imbalance in patients with LC, modulating the gut microbiota has emerged as a new therapeutic approach for the treatment of LC. Probiotics, which promote the growth of beneficial bacteria and reduce the growth of harmful bacteria, have particularly gained attention for their therapeutic effects on various liver diseases[12,13]. For instance, supplementation with *Lactobacillus casei* (*L. casei*) can improve lipid metabolism and regulate intestinal flora disorders in patients with alcoholic liver injury[14]. However, *L. rhamnosus* and its culture medium can ameliorate alcohol-induced liver function damage and steatosis[15]. Supplementation with *Lactobacillus*, *Bifidobacterium*, *Escherichia coli*, *Clostridium butyricum*, *Streptococcus salivarius*, and VSL#3 strains has shown promise in improving hepatic encephalopathy[16,17]. Although numerous studies have confirmed the effectiveness of probiotics in the treatment of liver disease in animal models and hospitalized patients, controversies remain, and limited options are available for probiotic selection in patients with hepatitis B virus-induced LC (HBC), necessitating further investigation of their efficacy[18].

N1115 is a ready-to-eat supplement containing fructooligosaccharides (FOS), lactitol, *Lactobacillus paracasei* N1115 (LP N1115), *L. plantarum*, *Bifidobacterium bifidobacterium*, and *L. acidophilus*, with LP N1115 accounting for > 80% of its composition. LP N1115 is isolated from traditional fermented dairy products and has probiotic effects, such as acid resistance, bile salt tolerance, and promotion of intestinal cell growth[19]. In combination with FOS, LP N1115 promotes recovery of the p38 mitogen-activated protein kinase pathway, enhances the expression of cohesin-1, improves intestinal barrier function, and preserves histological integrity[20]. The combined application of LP N1115 and FOS reduces endotoxin levels, inhibits the activation of the lipopolysaccharide (LPS)/Toll-like receptor 4 (TLR4) signaling pathway, decreases the release of inflammatory factors, and alleviates NAFLD-related insulin resistance in mice[21]. Stadlbauer *et al* demonstrated that *L. casei* preparations regulated the expression of TLR4, promoted interleukin (IL)-10 secretion, and restored neutrophil phagocytic ability in patients with ALD[22]. However, it remains unclear whether the complex ready-to-eat LP N1115 supplement can modulate the prognosis of patients with HBC by regulating the gut microbiota.

Based on the aforementioned background, this study recruited 160 HBC patients and evaluated them by comparing the changes in microbiota before and after probiotic treatment as well as the changes in the levels of inflammatory factors and liver function to assess whether LP N1115 had beneficial effects on the gut microbiota in HBC patients.

MATERIALS AND METHODS

Study participants

A total of 160 patients diagnosed with HBC and treated at the General Hospital of Ningxia Medical University between October 2018 and December 2020 were enrolled in this study. Patients were randomly divided into two groups. The intervention group consisted of 86 patients who received LP N1115 supplementation in addition to general treatment for 3 months. Stool samples were collected at baseline and at the end of the intervention (54 patients did not provide stool samples after the intervention owing to the use of antibiotics or proton pump inhibitors during LP N1115 treatment). The nonintervention group consisted of 74 patients who received general treatment only. The diagnosis of HBC was based on the guidelines for the prevention and treatment of chronic hepatitis B (2019 edition) issued by the Chinese Society of Hepatology and Chinese Society of Infectious Diseases[23]. The exclusion criteria were as follows: (1) Patients with alcoholic, autoimmune, or fatty liver disease, with acquired immunodeficiency, or with other viral liver diseases or other liver diseases; (2) patients with hypertension, diabetes, obesity, metabolic syndrome, inflammatory bowel disease, autoimmune disease (such as rheumatoid arthritis or multiple sclerosis) or various tumors; (3) patients who had not used antibiotics, microecological agents, or proton pump inhibitors within 2 wk before enrollment; and (4) pregnant and lactating women. This study was approved by the Medical Ethics Committee of the General Hospital of Ningxia Medical University (approval number: 2016-252), and all participants provided informed consent.

Clinical data

The Laboratory Department of the General Hospital of Ningxia Medical University conducted blood tests for high-sensitivity C-reactive protein (CRP), endotoxin, total bilirubin (TBIL), creatinine (Cr), albumin (Alb), prothrombin time (PT), and the prothrombin international standard ratio (INR). Abdominal color Doppler ultrasound was performed in the Department of Ultrasound at Ningxia Medical University.

The Child-Turcotte-Pugh (CTP)[24] scoring system was used as a clinical classification standard to quantitatively assess liver reserve function in patients with LC.

The Model for End-Stage Liver Disease (MELD) score was used to assess disease severity. The formula was as follows: $r = 0.378 \ln [\text{bilirubin (mg/dL)}] + 1.12 \ln (\text{INR}) + 0.95 \ln [\text{Cr (mg/dL)}] + 0.64$ (cause: Biliary or alcoholic 0, others 1). A higher R value indicated a greater risk and lower survival rate.

The prognostic index (PI)[25], which is based on serum CRP levels and white blood cell (WBC) counts, primarily reflects acute inflammation in the body. A CRP level of ≤ 10 mg/L and WBC count of $\leq 11 \times 10^9$ /L score 0 points; CRP ≤ 10 mg/L and WBC count $> 11 \times 10^9$ /L score 1 point; CRP > 10 mg/L and WBC count $\leq 11 \times 10^9$ /L score 1 point; CRP > 10 mg/L and WBC count $> 11 \times 10^9$ /L score 2 points.

Selection of probiotics

The probiotic used in this study was LP N1115, which was produced by Shijiazhuang Junlebao Dairy Co., Ltd. (Shijiazhuang City, China) and contains fructooligosaccharides, the food additive lactitol, LP N1115, *L. plantarum*, *Bifidobacterium bifidum*, and *L. acidophilus*. The dosage of active *Lactobacillus* added was $\geq 5 \times 10^{10}$ CFU per bag, with each bag weighing 2 g. The probiotic was administered by mixing an appropriate amount of warm water or milk with the recommended dosage of one bag twice a day. The storage instructions recommend keeping the probiotics in a cool, dry, or refrigerated place.

Collection of feces

Fresh fecal samples were collected from the participants and promptly placed in liquid nitrogen tanks for preservation during transportation to the laboratory. The collection process involved weighing the fecal samples and repackaging them in sterile centrifuge tubes. Three samples were collected from each participant. The subpacked specimens were rapidly transferred to a low-temperature refrigerator at -80°C for frozen storage. The entire collection and repackaging process was completed within 30 min.

DNA extraction and sequencing of the fecal microbiota

All the samples were subjected to the same procedures for DNA extraction and polymerase chain reaction (PCR) amplification by the same laboratory staff. The samples were suspended in 790 μL of sterile lysis buffer [4 M guanidine thiocyanate, 10% N-lauroyl sarcosine, and 5% N-lauroyl sarcosine in 0.1 M phosphate buffer (pH 8.0)] in a 2 mL screw-cap tube containing 1 g of glass beads (0.1 mm; BioSpec Products, Inc., United States). This mixture was vortexed vigorously and then incubated at 70°C for 1 h. After incubation, the mixture was subjected to bead beating for 10 min at maximum speed. Bacterial DNA was extracted using an E.Z.N.A.® Stool DNA Kit (Omega Biotek, Inc., GA) following the manufacturer's instructions, which excluded lysis steps; the extracted DNA was stored at -20°C for further analysis.

The extracted DNA from each sample was used as the template for amplifying the V3-V4 region of the 16S rRNA gene. The primers F1 and R2 (5'-CCTTCGGGNGGCWGCAG-3' and 5'-GACTACHVGGGTATCTAATCC-3') corresponding to positions 341 to 805 of the *Escherichia coli* 16S rRNA gene were used to amplify the V3-V4 region of each fecal sample by

PCR. PCRs were run on an EasyCycler 96 PCR system (Analytik Jena Corp., AG). The products from different samples were indexed and mixed at equal ratios for sequencing using the MiSeq platform (Illumina, Inc., United States) according to the manufacturer's instructions.

Bioinformatic analysis

Clean data were extracted from the raw data using USEARCH software (version 11.0.667). The quality-filtered sequences were clustered into unique sequences and sorted in order of decreasing abundance to identify representative sequences using UPARSE according to the UPARSE operational taxonomic unit (OTU) analysis pipeline, and singletons were omitted from this step. OTUs were classified based on 97% similarity after chimeric sequences were removed using UPARSE (version 7.1; <http://drive5.com/uparse/>) and annotated using the SILVA reference database (SSU138) in qiime2-2020.11. Taxonomic analysis was performed on the representative sequences of the OTUs, and the community composition at each taxonomic level (domain, kingdom, phylum, class, order, family, genus, and species) was determined for each sample.

Statistical analysis

The Mann-Whitney U test (Wilcoxon rank-sum test) was used to compare the levels of CRP, endotoxin, and CTP between the two groups. The MELD score and PI were compared before and after treatment. $P < 0.05$ indicated statistical significance. The chi-square test was used to compare the incidence of ascites.

Bacterial α diversity was assessed using the Shannon, Simpson, Chao1, and The ACE estimator (ACE) indices. The Wilcoxon rank-sum test was also used to assess the α diversity among the different groups. The nonparametric factorial Kruskal-Wallis rank-sum test was used to detect differences in microbial abundances. Linear discriminant analysis (LDA) effect size (LEfSe) was used to detect taxa with differential abundance among the groups (LEfSe1.1, <https://github.com/SegataLab/Lefse>).

RESULTS

Baseline characteristics of the participants and changes in clinical indicators before and after treatment in the intervention group and nonintervention group

The baseline characteristics of the participants, including their clinical and biochemical characteristics, are summarized in Table 1. Before the intervention, no significant differences in age, sex, TBIL level, Cr level, PT time, WBC count, or platelet count were observed between the intervention and nonintervention groups. There were significant alterations observed in the levels of Alb, Cr, PT, INR, and CRP before and after treatment in the intervention group. Conversely, no notable changes were found in clinical parameters before or after treatment in the nonintervention group (Table 2).

Evaluation of liver function before and after treatment

The CTP and MELD scores were used to assess liver function before and after treatment in the intervention and nonintervention groups, respectively. The results showed that after treatment, the CTP score of the intervention group was better than that before treatment, with a decrease in the proportion of patients with CTP grade C disease from 25.68% to 12.16%. In contrast, the proportion of patients with CTP grade C disease in the nonintervention group increased from 31.08% to 33.78% (Figure 1A-D). Survival curves revealed that the probability of recurrence of ascites in the intervention group was significantly lower than that in the nonintervention group (Figure 1E).

The CTP grade in the intervention group significantly decreased after treatment ($P = 0.007$), whereas that in the nonintervention group did not significantly change ($P = 0.489$). The MELD score, which reflects the severity of end-stage liver disease, was not significantly different between the intervention and nonintervention groups before treatment, whereas after treatment, the MELD score of the intervention group was significantly lower than that of the nonintervention group ($P = 0.017$), indicating that the severity of liver disease was lower in the intervention group than in the nonintervention group (Figure 2).

Changes in inflammatory indices before and after treatment

The results showed no significant differences in CRP levels or PI between the intervention and nonintervention groups at baseline, whereas after the intervention, there were significant differences ($P < 0.001$ and $P = 0.001$, respectively). Compared with those in the pretreatment group, the CRP level and PI in the intervention group decreased significantly after treatment ($P < 0.001$ and $P = 0.006$, respectively), whereas there was no significant reduction in the nonintervention group after treatment ($P = 0.823$ and $P = 0.306$, respectively). The endotoxin levels were significantly lower after treatment in the intervention group ($P = 0.007$) (Figure 3).

Changes in the incidence of ascites before and after treatment

There was no significant difference in the incidence of ascites between the intervention and nonintervention groups before treatment ($P = 1.0$). After treatment with LP N1115, the incidence of ascites in the intervention group was significantly lower than that before treatment, whereas there was no significant change in the nonintervention group. The incidence of massive ascites decreased from 6.76% to 2.7% in the intervention group, whereas it increased from 8.11% to 12.16% in the nonintervention group. The incidence of ascites after treatment was significantly lower in the intervention group than in the nonintervention group ($P = 0.001$) (Figure 4).

Table 1 Baseline characteristics of the subjects

Characteristic	Treat (n = 86)	Untreat (n = 74)	P value
Age (yr), median (IQR)	58 (51.25, 64.75)	60 (51, 70)	0.219
Sex, n (%)			0.176
Male	68 (79.07)	53 (71.62)	
Female	18 (20.93)	21 (28.38)	
TBIL (3.0-22.0 μ mol/L)	29.26 (21.025, 43.095)	33.875 (26.168, 53.657)	0.117
Alb (35.0-50.0 g/L)	32.75 (25, 39.6)	30.745 (26.575, 34.825)	0.341
Cr (58-110 μ mol/L)	64.5 (54.45, 75.325)	60.55 (51.35, 76.925)	0.498
WBC ($3.5-9.5 \times 10^9$ /L)	3.89 (2.728, 5.578)	3.88 (2.9075, 5.06)	0.855
PLT ($125.0-350.0 \times 10^{12}$ /L)	78 (43.25, 110.25)	69 (48.25, 111.5)	0.943
PT (9.4-12.5 s)	16.15 (14.6, 18.125)	16.25 (14.625, 18.275)	0.986
INR (0.85-1.14)	1.345 (1.216, 1.518)	1.36 (1.193, 1.505)	0.907
CRP (< 10)	4.75 (1.74, 12.8)	4.995 (1.72, 9.403)	0.836

TBIL: Total bilirubin; Alb: Albumin; Cr: Creatinine; WBC: White blood cell; PLT: Platelet; PT: Prothrombin time; INR: International standard ratio; CRP: C-reactive protein.

Table 2 Changes in clinical indicators before and after treatment were compared between the intervention group and the nonintervention group

Characteristics	Treat		P value	Untreat		P value
	Before	After		Before	After	
TBIL (μ mol/L), median (IQR)	29.26 (21.025, 43.095)	27.515 (18.237, 44.22)	0.707	33.875 (26.168, 53.657)	33.3 (20.8, 57.315)	0.637
Alb (g/L), median (IQR)	32.75 (25, 39.6)	37.85 (31.635, 43.773)	0.007	30.745 (26.575, 34.825)	29.9 (26.775, 38.025)	0.625
Cr (μ mol/L), median (IQR)	64.5 (54.45, 75.325)	0.85 (48.425, 69.325)	0.03	60.55 (51.35, 76.925)	61.9 (51.4, 82.125)	0.689
WBC (10^9 /L), median (IQR)	3.89 (2.7275, 5.5775)	3.505 (2.383, 5.155)	0.321	3.88 (2.9075, 5.06)	4.115 (3, 5.493)	0.439
PLT (10^{12} /L), median (IQR)	78 (43.25, 110.25)	71.5 (50.25, 123.25)	0.760	69 (48.25, 111.5)	69 (48.25, 103.75)	0.833
PT (s), median (IQR)	16.15 (14.6, 18.125)	15.05 (13.35, 16.6)	0.003	16.25 (14.625, 18.275)	15.95 (14, 17.75)	0.342
INR, median (IQR)	1.345 (1.216, 1.518)	1.29 (1.123, 1.408)	0.018	1.36 (1.193, 1.505)	1.315 (1.185, 1.448)	0.526
CRP, median (IQR)	4.75 (1.74, 12.8)	1.845 (0.775, 4.343)	0.005	4.995 (1.72, 9.403)	1.985 (2.035, 1.015)	0.822

TBIL: Total bilirubin; Alb: Albumin; Cr: Creatinine; WBC: White blood cell; PLT: Platelet; PT: Prothrombin time; INR: International standard ratio; CRP: C-reactive protein.

Changes in the intestinal flora before and after treatment in the intervention group

Venn diagram of the OTU distribution: The microbiota in a total of 118 fecal samples collected from the intervention group were tested, including 86 samples collected before the intervention and 32 samples after the intervention. A Venn diagram showed that there were 1744 OTUs shared in the samples before and after treatment, while 1541 OTUs were specifically detected before treatment, and 372 OTUs were specifically detected after treatment (Figure 5).

Alpha diversity analysis: Alpha diversity was used to assess the richness (Chao1 and ACE) and diversity (Shannon and Simpson indices) of the gut microbiota. Alpha-diversity analysis of the intervention group revealed changes in the bacterial richness and diversity before and after treatment. The richness of the intestinal flora tended to increase after the intervention, but the difference was not significant ($P > 0.05$). The Simpson index was significantly lower after the intervention than before the intervention ($P < 0.05$), indicating that the diversity of the intestinal flora tended to increase after intervention with probiotics (Figure 6).

Composition of the intestinal flora before and after probiotic treatment: At the phylum level, Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria and Fusobacteria were the main phyla identified both before and after treatment. However, the proportion of each phylum changed after the treatment: the proportion of Bacteroidetes (25.2%-35.3%)




Figure 1 Proportions of Child-Turcotte-Pugh grades A, B, and C before and after treatment in the intervention and nonintervention groups and Kaplan-Meier survival curves. A: The proportion of Child-Turcotte-Pugh (CTP) grades A, B, and C before treatment in the intervention group; B: The proportions of patients with CTP grades A, B, and C in the intervention group after treatment with *Lactobacillus paracasei* N1115; C: The proportions of patients with CTP grades A, B, and C in the nonintervention group before treatment; D: The proportions of patients with CTP grades A, B, and C in the nonintervention group after treatment; E: The probability of recurrence of ascites in the intervention and nonintervention groups. CTP: Child-Turcotte-Pugh.




Figure 2 Comparison of liver function indices between the intervention and nonintervention groups before and after treatment. A: A comparison of Child-Turcotte-Pugh grades between the two groups; B: A comparison of Model for End-Stage Liver Disease scores between the two groups. ^a $P < 0.01$, ^b $P < 0.001$.

increased significantly, and those of Firmicutes (61.8%-51.7%) and Proteobacteria (10.5%-5.6%) decreased significantly (Table 3 and Figure 7).

The main genera identified before and after treatment were *Bacteroides*, *Faecalibacterium*, *Lachnospiraceae incertae sedis*, and *Ruminococcaceae unclassified*. However, after treatment, the proportions of the potentially pathogenic bacteria *Enterobacteriaceae unclassified* (2.6%-0.7%), *Escherichia*, *Shigella* (5%-1.8%), and *Streptococcus* (1.8%-0.6%) decreased in abundance. In contrast, the proportions of *Bacteroides* (19.8%-28.4%), *Bifidobacterium* (1.6%-4%), *Ruminococcus* (0.7%-1.5%), *Prevotella* (2.4%-4.9%), and *Lachnospiraceae incertae sedis* (4.8%-5.0%) increased (Table 3 and Figure 8).

Comparison of the abundance of flora before and after treatment: LEfSe analysis was used to identify the key phylotypes with significant differences in abundance before and after treatment. LEfSe analysis revealed that, compared to those before treatment, the proportions of Firmicutes (LDA = 4.74, $P = 0.05$), *Clostridium* (LDA = 3.8, $P = 0.03$), *Pseudobutyrvibrio* (LDA = 3.5, $P = 0.03$), and *Anaerostipes* (LDA = 3.46, $P = 0.01$) significantly decreased after treatment. In contrast, the proportions of Bacteroidetes (LDA = 4.66, $P = 0.01$), *Bifidobacterium* (LDA = 4.47, $P = 0.04$), Veillonellaceae (LDA = 4.0, $P = 0.01$), Lachnospiraceae (LDA = 3.95, $P = 0.001$) and *Eggerthella* (LDA = 3.47, $P = 0.01$) significantly

Table 3 Proportions of intestinal flora at the phylum and genus levels in all subjects in the intervention group before and after treatment

Phylum of bacteria (%)	GR	ZL	P value
Firmicutes	61.8	51.7	0.046
Bacteroidetes	25.2	35.5	0.008
Proteobacteria	10.5	5.6	0.468
Actinobacteria	1.7	4	0.057
Fusobacteria	0.3	0.8	0.494
Bacteroides	19.8	28.4	0.014
Faecalibacterium	22	17.8	0.803
Lachnospiraceae_Incertae_Sedis	4.8	5	0.001
Ruminococcaceae_uncultured	5.4	2.6	0.027
Escherichia-Shigella	5	1.8	0.348
Subdoligranulum	4.5	2.3	0.561
Prevotella	2.4	4.9	0.211
Veillonella	3	1.3	0.315
Bifidobacterium	1.6	3.9	0.039
Enterobacteriaceae_unclassified	2.6	0.7	0.629
Anaerostipes	1	0.6	0.007

GR: Before treatment with *Lactobacillus paracasei* N1115 (LP N1115); ZL: 3 months after treatment with LP N1115.




Figure 3 Comparison of inflammatory indices between the intervention and nonintervention groups before and after treatment. A: A comparison of C-reactive protein levels between the two groups; B: A comparison of endotoxin levels between the two groups; C: A comparison of the prognostic index between the two groups. ^a $P < 0.001$, ^b $P < 0.01$. CRP: C-reactive protein; PI: prognostic index.

increased after treatment (Figure 8).

Correlation analysis between differential flora and CTP classification: To further understand the relationship between the differential bacteria and the patient's CTP classification of liver function, we performed a correlation analysis between the differential flora and the CTP classification. There was no correlation between the occurrence of *Veillonella*, *Streptococcus*, or *Lachnospiraceae incertae sedis* and the CTP classification before treatment. However, after treatment, there was a positive correlation (Table 4).

DISCUSSION

Intestinal flora imbalance in patients with decompensated LC has garnered significant attention[8]. Studies have indicated that the intestinal microbiota may contribute to the progression of HBV-related chronic liver disease to severe liver failure by promoting the accumulation of inflammatory factors and pathogenic metabolites[26]. An imbalanced

Table 4 Correlations between genus and Child-Turcotte-Pugh classification score before and after intervention

	GR		ZL	
	<i>r</i>	<i>P</i> value	<i>r</i>	<i>P</i> value
Bacteroides	-0.436	0.013	-0.004	0.981
Lachnospiraceae_Incertae_Sedis	0.312	0.082	0.353	0.048
Veillonella	0.272	0.132	0.449	0.01
Streptococcus	0.143	0.433	0.354	0.047
Escherichia-Shigella	0.275	0.128	0.016	0.929
Prevotella	0.22	0.226	0.069	0.706
Enterobacteriaceae_unclassified	0.366	0.04	0.198	0.277
Firmicutes/Bacteroidetes	0.299	0.097	0.253	0.126

GR: Before treatment with *Lactobacillus paracasei* N1115 (LP N1115); ZL: 3 months after treatment with LP N1115.




Figure 4 Occurrence of ascites before and after treatment in the intervention and non-intervention groups. A: No ascites; B: Small ascites; C: Moderate ascites; D: Large ascites.




Figure 5 Venn analysis of the distribution of operational taxonomic units. GR: Before treatment with *Lactobacillus paracasei* N1115 (LP N1115); ZL: 3 months after treatment with LP N1115.

intestinal ecology in patients with LC can lead to impaired intestinal barrier function and microbial translocation, which in turn contributes to the development of SBP[27]. Moreover, intestinal flora imbalance after disruption of intestinal barrier function results in increased levels of *Klebsiella* and *Proteus* spp., which, through the production of ammonia and endotoxins, directly causes hepatic encephalopathy owing to an increase in blood ammonia levels[28]. Patients with HCC often exhibit elevated levels of gram-negative bacteria commonly found in the gut microbiome, such as *Escherichia coli*, and decreased levels of beneficial bacteria, including *Lactobacillus*, *Bifidobacterium*, and *Enterococcus*. This imbalance is primarily caused by increased intestinal permeability, leading to bacterial translocation and endotoxin accumulation, which in turn results in intestinal bacterial overgrowth and alterations in the composition of the intestinal microbiota[29].




Figure 6 Comparison of gut microbiota abundance and diversity before and after intervention in patients. A: Differences in the Ace index between groups; B: Differences in the Chao index between groups; C: Differences in the Shannon index between groups; D: Differences in the Simpson index between groups. GR: Before treatment with *Lactobacillus paracasei* N1115 (LP N1115); ZL: 3 months after treatment with LP N1115.

A previous study involving patients with HBC demonstrated no significant differences in alpha diversity among patients with HBV-related chronic diseases, HBC, or HCC[30]. However, in the present study, the results indicated an increasing trend in gut microbiota diversity after treatment.

L. paracasei ameliorated diarrhea by inhibiting activation of the NF- κ B-MLCK pathway and increasing the abundance of gut microbiota that produce short-chain fatty acids (SCFA)[31]. Lp N1115 was able to enhance the content of *Lactobacillus* and maintain fecal pH levels. Its beneficial effects on gut development were more obvious in 6-12-month-old infants [32]. These findings suggest that intervention with the N1115 ready-to-eat *Lactobacillus* supplement may have a modulatory effect on gut microbiota dysbiosis in patients with LC. The increased diversity of the gut microbiota after treatment may help restore a healthy gut state. However, further studies are required to validate and explore the effect-




Figure 7 Plots of the relative abundance of the gut microbiota at the phylum and genus levels before and after treatment in all patients. A: Plots of the relative abundance of the gut microbiota at the phylum levels before and after treatment in all patients; B: Plots of the relative abundance of gut microbiota at the genus levels before and after treatment in all patients. GR: Before treatment with *Lactobacillus paracasei* N1115 (LP N1115); ZL: 3 months after treatment with LP N1115.

iveness and mechanisms of this intervention.

Although numerous studies have confirmed the efficacy of probiotics in animal models and in the treatment of hospitalized patients with liver disease, several controversies remain. The choice between single or combined probiotics as well as the efficacy of different bacterial combinations in different probiotics for chronic liver disease require further investigation. Interestingly, we found a close relationship among dysbiosis, inflammatory markers, and liver function. The partial recovery of inflammatory marker levels and liver function in patients after LP N1115 intervention was even more




Figure 8 Histogram of linear discriminant analysis effect size distribution; evolutionary subplots were analyzed. A: Histogram of linear discriminant analysis effect size distribution; The evolutionary subplots were analyzed. TLEfse analyzed the LDA histogram; B: Histogram of linear discriminant analysis effect size distribution; The evolutionary subplots were analyzed. LEfse analyzed LDA evolutionary cladistics. GR: Before treatment with *Lactobacillus paracasei* N1115 (LP N1115); ZL: 3 months after treatment with LP N1115.

surprising. Our study demonstrated a significant decrease in CRP levels and a lower CRP level in the intervention group than in the nonintervention group after treatment. Moreover, endotoxin synthesis decreased in the intervention group. The PI, which reflects acute inflammation in the body, significantly decreased in the intervention group after treatment and was significantly lower than that in the nonintervention group, suggesting improved acute inflammation in the intervention group after treatment, whereas the nonintervention group receiving conventional treatment exhibited no significant changes. Patients with HBC often experience bacterial translocation and increased endotoxin levels, leading to changes in intestinal permeability and increased activation of the LPS/TLR4 signaling pathway in the liver[4,33]. TLR4 activation triggers the production of proinflammatory, antiviral, and antibacterial cytokines. The levels of IL-10 and tumor necrosis factor- α are significantly greater in HBC patients than in control individuals, and increased endotoxin expression promotes factor synthesis through signaling pathways[19,34,35]. *L. casei* preparations can regulate TLR4 expression and IL-10 secretion. Therefore, we propose that LP N1115 inhibits the activation of the LPS/TLR4 signaling pathway, reduces the release of inflammatory factors, and effectively alleviates the inflammatory state of patients when combined with conventional treatment[36].

However, whether there is a correlation between intestinal flora imbalance and liver function needs to be further explored. The main pathophysiological changes in patients with LC are liver function impairment and portal hypertension, which are crucial factors to consider when evaluating disease conditions and prognosis. Widely used evaluation systems, such as the CTP classification and MELD score, are commonly used both domestically and internationally. An imbalance in the gut microbiota can trigger an inflammatory response and exacerbate liver fibrosis by activating TLRs, thereby promoting the progression of cirrhosis to decompensation and liver failure[27]. Probiotics have been found to reduce liver function damage and improve the levels of markers, such as alanine aminotransferase, aspartate aminotransferase, cholesterol, low-density lipoprotein, and triglycerides, and waist circumference in children with NAFLD[37]. One study showed that Bullavirinae, Felixounavirus, Streptococcus, Escherichia and Pseudomonas phages were positively linked with the MELD, whereas Faecalibacterium phages were negatively linked with the MELD [38]. In this study, we aimed to further understand the effects of LP N1115, a ready-to-eat *Lactobacillus* supplement, on liver function. We compared the CTP and MELD scores between the intervention and nonintervention groups before and after the intervention. The results showed a significant improvement in the CTP classification score and a decrease in the MELD score after the intervention. We further validated liver function by assessing the incidence of ascites. The incidence of ascites in patients treated with LP N1115 was significantly lower, including a lower incidence of massive ascites, than that in patients who did not receive the N1115 intervention and who only received conventional treatment during the same period. Therefore, LP N1115 is highly important for improving liver function and liver reserve function in patients.

In patients with HBC, an increase in the proportion of Enterobacteriaceae, Fusobacteriaceae, and alkali-producing bacteria in the gut was observed, accompanied by a decrease in the abundance of Ruminococcaceae and Pilosporillaceae. Many bacteria from the Ruminococcaceae and Pilosporillaceae families possess bile acid hydrolases that are closely associated with the production of secondary bile acids[27]. Bile acids can disrupt the gut barrier and immune function, affecting the regulation of the intestinal flora structure. At the phylum level, the dominant species remained consistent before and after treatment, although the proportion of each phylum changed. After treatment, the abundance of some potentially pathogenic bacteria decreased, whereas that of beneficial bacteria increased. LEfSe analysis revealed significant differences in the abundance of *Bacteroides*, *Bifidobacterium*, *Lachnospirillaceae*, and *Eggerthella* after treatment. These results are consistent with the relative abundance map of the dominant species, suggesting that LP N1115 effectively regulates the homeostasis of the intestinal flora. Surprisingly, we found a significant difference in *Lachnospiraceae incertae sedis* levels after N1115 intervention, which was positively correlated with the CTP classification score. Previous studies by Bajaj et al[8] indicated that beneficial bacteria, such as Spirillaceae and Verrucomicrobacteriaceae, decrease in abundance in the intestines of patients with LC, whereas harmful bacteria, such as Enterobacteriaceae and Bacteroidaceae, increase in abundance. *Triclospora*, a member of *Lachnospiraceae incertae sedis*, produces anti-inflammatory SCFA that help maintain water and electrolyte balance, improve intestinal mucosa function and morphology, inhibit tumor cell proliferation, induce macrophage apoptosis, inhibit histone deacetylation, promote the migration of regulatory T cells, and induce the production of anti-inflammatory IgA by mucosal B cells[39,40]. *Lachnospiraceae incertae sedis* possesses bile salt hydrolase, which is involved in secondary bile acid production. Bile acids can directly damage bacterial outer membranes and exert bactericidal effects. These bacteria can also generate nitric oxide and IL-18 through the "bile acid-G protein-coupled receptor (targeting of bile acid receptor 5) TGR5-farnesoid X receptor-camp" pathway, thereby influencing the intestinal flora via the immune system, which plays a crucial role in maintaining the balance of the intestinal flora[39,41]. Additionally, the liver secretes bile acids into the intestine through the biliary tract, which can affect the composition and abundance of the intestinal flora. LC is often accompanied by bile acid excretion disorders. Patients with decompensated cirrhosis may develop portal hypertension, leading to intestinal mucosal congestion, edema, impaired small intestinal motility, and intestinal content retention. Complications such as esophageal and gastric fundus variceal bleeding are accompanied by intestinal mucosal ischemia/reperfusion injury, leading to bacterial overgrowth and translocation to the small intestine[42]. Qin et al[42] reported that the intestinal flora of patients with LC contained a high proportion of oral bacteria, such as *Streptococcus* and *Veillonella*, indicating that the oral microbial flora invades the gut and contributes to LC deterioration. Reduced gastric acid secretion and altered bile acid secretion in patients with LC may facilitate the translocation of oral bacteria to the gut. Similarly, we observed an increased proportion of *Streptococcus* and *Veillonella* before the intervention, although this difference was not correlated with the CTP classification score. However, after the intervention, the proportion of patients who died decreased and was positively correlated with the CTP classification score. Therefore, we believe that LP N1115 may influence the level of intestinal bile acid by regulating the level of *Lachnospiraceae incertae sedis*, reducing the translocation of *Streptococcus* and *Veillonella* to the intestine, and assisting conventional treatment to improve inflammation levels and liver function in patients with hepatobiliary diseases, thereby significantly affecting patient prognosis.

Wang *et al*[43] discovered that patients with hepatitis B-decompensated cirrhosis exhibited a significant reduction in the abundance of Firmicutes, Trichosporillum, Dorea, and Dialister. Conversely, there was a significant increase in the abundance of Streptococcus, Fusobacterium, Veillonella, and Haemophilus spp. In our analysis of patients with HBC at the phylum level, we observed a relatively high proportion of Firmicutes before the intervention, which decreased after the intervention, demonstrating slight differences from previous studies. We think that a phylum-based analysis is generally not applicable to patients with cirrhosis because of the inclusion of pathogenic groups, such as staphylococci and Enterococcaceae, within Firmicutes, which are more abundant in severely ill individuals. Following the intervention with LP N1115, the proportions of cocci and Enterococcaceae within the phylum Firmicutes decreased.

This study is limited by its small sample size, single-center analysis, absence of an intervention treatment in the control group and no additional stratification. Therefore, whether the effects of the N1115 ready-to-eat *Lactobacillus* supplement on the intestinal flora are limited by differences in region and dietary habits is unknown; additionally, whether the changes in the intestinal flora in patients with different complications are consistent needs to be further explored. Our future work will involve designing larger multicenter trials.

CONCLUSION

In conclusion, we propose that LP N1115 modulates intestinal bile acid levels by regulating the abundance of *Lachnospiraceae incertae sedis*, consequently reducing the translocation of *Streptococcus* and *Veillonella* to the intestine. This intervention can effectively complement conventional treatments, leading to improvements in inflammation and liver function in HBC patients. As a potential therapeutic target, it is crucial to consider the timing, duration, and dosage of this intervention. Therefore, conducting large-scale, multicenter, randomized, placebo-controlled trials investigating the microbiome and metabolomics of LP N1115-treated patients with HBC in the future would provide valuable insights.

ARTICLE HIGHLIGHTS

Research background

Hepatitis B cirrhosis (HBC) is a prevalent chronic disease associated with significant morbidity and mortality. Numerous studies have consistently demonstrated the occurrence of intestinal flora dysbiosis in patients diagnosed with HBC. Alterations in the composition of the intestinal flora can disrupt immune regulation, impair intestinal barrier function, and induce systemic inflammatory changes *via* the gut-liver axis, thereby hastening the progression of cirrhosis. Interventions utilizing microecological preparations hold immense significance in enhancing prognosis.

Research motivation

Although numerous individual probiotics have been documented in relation to HBC, the impact of the N1115 compound ready-to-eat *Lactobacillus* supplement in patients with HBC remains uncertain.

Research objectives

The primary objective was to assess the impact of the N1115 ready-to-consume lactic acid bacterial supplement on hepatic function, inflammation, and ascites in patients with HBC. This study aimed to investigate the therapeutic potential of the intestinal microecology in managing HBC. HBC patients were administered the N1115 ready-to-eat lactic acid bacterial supplement for 3 months, which resulted in a significant increase in intestinal microbial diversity and notable alterations in the composition of the intestinal microbiota. There was a remarkable improvement in liver function parameters and a decrease in the levels of inflammatory markers among the patients. This investigation offers novel insights into optimizing interventions targeting the intestinal microflora in individuals with HBC.

Research methods

This study included 160 HBC patients who were diagnosed at the General Hospital of Ningxia Medical University between October 2018 and December 2020. Patients were randomly divided into an intervention group that received *Lactobacillus paracasei* N1115 (LP N1115) supplementation along with routine treatment and a control group that received routine treatment only. Fecal samples were collected at the onset and conclusion of the 12-wk intervention period. The structure of the intestinal microbiota and the levels of serological indicators, such as liver function and inflammatory factors, were assessed.

Research results

The patients were assessed after 3 months of treatment with the N1115 ready-to-eat *Lactobacillus* supplement: (1) There were significant changes in the levels of albumin, creatinine, prothrombin time, international standard ratio, and C-reactive protein and in the Child-Turcotte-Pugh and Model for End-Stage Liver Disease scores before and after treatment in the intervention group; (2) the probability of recurrence of ascites in the intervention group was significantly lower than that in the nonintervention group; and (3) the diversity of the intestinal flora tended to increase after intervention with probiotics. At the phylum level, the proportion of Bacteroidetes increased significantly, and those of Firmicutes and Proteobacteria decreased significantly. At the genus level, the proportions of the potentially pathogenic bacteria

Enterobacteriaceae_unclassified, Escherichia, Shigella, and Streptococcus decreased. In contrast, the proportions of Bacteroides, Bifidobacterium, Ruminococcus, Prevotella, and Lachnospiraceae incertae sedis increased.

Research conclusions

LP N1115 supplementation is promising for ameliorating intestinal microbial imbalance in patients with HBC by modulating the structure of the intestinal microbiota, improving liver function, and reducing inflammatory factor levels.

Research perspectives

Future studies should prioritize investigating the structural and metabolic alterations in the composition of intestinal biota among patients with various complications of HBC, along with elucidating their underlying mechanisms. To address these inquiries, our research group intends to conduct large-scale, long-term clinical trials.

ACKNOWLEDGEMENTS

We thank all the patients who participated in this study and the physicians in the Department of Infectious Diseases, General Hospital, Ningxia Medical University. We also thank Shanghai Mobio Biomedical Technology Co. for their technical support.

FOOTNOTES

Author contributions: Ding XC is the guarantor and designed the study; Hu YC participated in the acquisition, analysis, and interpretation of the data and drafted the initial manuscript; Liu HJ, Ma WL, and Feng XY participated in the acquisition and analysis of the data; and Ding XC and Ma LN critically revised the article for important intellectual content.

Supported by The Health System Research Project of Ningxia Hui Autonomous Region of China, No. 2022-NWKY-061.

Institutional review board statement: The study was reviewed and approved by the Hungarian National Review Board and the Institutional Review Board of the Ningxia Medical University.

Clinical trial registration statement: This study is registered at <http://www.chictr.org.cn>. The registration identification number is ChiCTR1817011061.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Data sharing statement: Technical appendix, statistical code, and dataset available from the corresponding author at [13619511768@163.com]. Participants consent for data sharing was not obtained but the presented data are anonymized and risk of identification is low. No additional data are available.

CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Yan-Chao Hu [0000-0002-5570-5222](#); Xiang-Chun Ding [0000-0003-0283-9419](#); Hui-Juan Liu [0009-0001-2741-9659](#); Wan-Long Ma [0009-0007-3658-1571](#); Xue-Yan Feng [0009-0000-5773-0862](#); Li-Na Ma [0000-0002-6244-7997](#).

S-Editor: Qu XL

L-Editor: A

P-Editor: Cai YX

REFERENCES

- 1 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. *Lancet* 2021; **398**: 1359-1376 [PMID: [34543610](#) DOI: [10.1016/S0140-6736\(21\)01374-X](#)]

- 2 **Yang F**, Ma L, Yang Y, Liu W, Zhao J, Chen X, Wang M, Zhang H, Cheng S, Shen F, Wang H, Zhou W, Cao G. Contribution of Hepatitis B Virus Infection to the Aggressiveness of Primary Liver Cancer: A Clinical Epidemiological Study in Eastern China. *Front Oncol* 2019; **9**: 370 [PMID: 31179237 DOI: 10.3389/fonc.2019.00370]
- 3 **Fouts DE**, Torralba M, Nelson KE, Brenner DA, Schnabl B. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. *J Hepatol* 2012; **56**: 1283-1292 [PMID: 22326468 DOI: 10.1016/j.jhep.2012.01.019]
- 4 **Lee NY**, Yoon SJ, Han DH, Gupta H, Youn GS, Shin MJ, Ham YL, Kwak MJ, Kim BY, Yu JS, Lee DY, Park TS, Park SH, Kim BK, Joung HC, Choi IS, Hong JT, Kim DJ, Han SH, Suk KT. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. *Gut Microbes* 2020; **11**: 882-899 [PMID: 31965894 DOI: 10.1080/19490976.2020.1712984]
- 5 **Duseja A**, Acharya SK, Mehta M, Chhabra S, Shalimar, Rana S, Das A, Dattagupta S, Dhiman RK, Chawla YK. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. *BMJ Open Gastroenterol* 2019; **6**: e000315 [PMID: 31423319 DOI: 10.1136/bmjgast-2019-000315]
- 6 **Bajaj JS**. Altered Microbiota in Cirrhosis and Its Relationship to the Development of Infection. *Clin Liver Dis (Hoboken)* 2019; **14**: 107-111 [PMID: 31632660 DOI: 10.1002/cld.827]
- 7 **Chen Y**, Yang F, Lu H, Wang B, Chen Y, Lei D, Wang Y, Zhu B, Li L. Characterization of fecal microbial communities in patients with liver cirrhosis. *Hepatology* 2011; **54**: 562-572 [PMID: 21574172 DOI: 10.1002/hep.24423]
- 8 **Bajaj JS**, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications. *J Hepatol* 2014; **60**: 940-947 [PMID: 24374295 DOI: 10.1016/j.jhep.2013.12.019]
- 9 **Acharya C**, Bajaj JS. Altered Microbiome in Patients With Cirrhosis and Complications. *Clin Gastroenterol Hepatol* 2019; **17**: 307-321 [PMID: 30099098 DOI: 10.1016/j.cgh.2018.08.008]
- 10 **Brescia P**, Rescigno M. The gut vascular barrier: a new player in the gut-liver-brain axis. *Trends Mol Med* 2021; **27**: 844-855 [PMID: 34229973 DOI: 10.1016/j.molmed.2021.06.007]
- 11 **Wang R**, Tang R, Li B, Ma X, Schnabl B, Tilg H. Gut microbiome, liver immunology, and liver diseases. *Cell Mol Immunol* 2021; **18**: 4-17 [PMID: 33318628 DOI: 10.1038/s41423-020-00592-6]
- 12 **Pessione E**. Lactic acid bacteria contribution to gut microbiota complexity: lights and shadows. *Front Cell Infect Microbiol* 2012; **2**: 86 [PMID: 22919677 DOI: 10.3389/fcimb.2012.00086]
- 13 **Shin D**, Chang SY, Bogere P, Won K, Choi JY, Choi YJ, Lee HK, Hur J, Park BY, Kim Y, Heo J. Beneficial roles of probiotics on the modulation of gut microbiota and immune response in pigs. *PLoS One* 2019; **14**: e0220843 [PMID: 31461453 DOI: 10.1371/journal.pone.0220843]
- 14 **Ren T**, Huang C, Cheng M. Dietary blueberry and bifidobacteria attenuate nonalcoholic fatty liver disease in rats by affecting SIRT1-mediated signaling pathway. *Oxid Med Cell Longev* 2014; **2014**: 469059 [PMID: 25544867 DOI: 10.1155/2014/469059]
- 15 **Zhang M**, Wang C, Zhao H, Zhao C, Chen Y, Wang Y, McClain C, Feng W. Enhanced AMPK phosphorylation contributes to the beneficial effects of Lactobacillus rhamnosus GG supernatant on chronic-alcohol-induced fatty liver disease. *J Nutr Biochem* 2015; **26**: 337-344 [PMID: 25622859 DOI: 10.1016/j.jnutbio.2014.10.016]
- 16 **Holte K**, Krag A, Gluud LL. Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. *Hepatol Res* 2012; **42**: 1008-1015 [PMID: 22548675 DOI: 10.1111/j.1872-034X.2012.01015.x]
- 17 **Lunia MK**, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. *Clin Gastroenterol Hepatol* 2014; **12**: 1003-8.e1 [PMID: 24246768 DOI: 10.1016/j.cgh.2013.11.006]
- 18 **Ren YD**, Ye ZS, Yang LZ, Jin LX, Wei WJ, Deng YY, Chen XX, Xiao CX, Yu XF, Xu HZ, Xu LZ, Tang YN, Zhou F, Wang XL, Chen MY, Chen LG, Hong MZ, Ren JL, Pan JS. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. *Hepatology* 2017; **65**: 1765-1768 [PMID: 28027582 DOI: 10.1002/hep.29008]
- 19 **Acharya C**, Bajaj JS. Gut Microbiota and Complications of Liver Disease. *Gastroenterol Clin North Am* 2017; **46**: 155-169 [PMID: 28164848 DOI: 10.1016/j.gtc.2016.09.013]
- 20 **Yao F**, Jia R, Huang H, Yu Y, Mei L, Bai L, Ding Y, Zheng P. Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. *Arch Med Sci* 2019; **15**: 1336-1344 [PMID: 31572482 DOI: 10.5114/aoms.2019.86611]
- 21 **Yao FF**, Zheng PY, Huang H, Bai LM, Ding YR, Mei L, Liu SM. [Effects of Lactobacillus paracasei N1115 combined with fructooligosaccharides on non-alcoholic fatty liver disease induced by high-fat diet in mice]. *Zhonghua Gan Zang Bing Za Zhi* 2017; **25**: 927-933 [PMID: 29325294 DOI: 10.3760/cma.j.issn.1007-3418.2017.12.008]
- 22 **Stadlbauer V**, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. *J Hepatol* 2008; **48**: 945-951 [PMID: 18433921 DOI: 10.1016/j.jhep.2008.02.015]
- 23 **Chinese Society of Infectious Diseases**; Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. [The guidelines of prevention and treatment for chronic hepatitis B (2019 version)]. *Zhonghua Gan Zang Bing Za Zhi* 2019; **27**: 938-961 [PMID: 31941257 DOI: 10.3760/cma.j.issn.1007-3418.2019.12.007]
- 24 **Zuberi BF**, Rasheed T, Ali FS, Bader N, Sadaf R. Assessment of frailty in cirrhosis using bedside measures and its correlation with Child-Turcotte-Pugh, MELD & MELD-Na Scores. *Pak J Med Sci* 2022; **38**: 1086-1092 [PMID: 35799712 DOI: 10.12669/pjms.38.5.5545]
- 25 **Yang KL**, Chen JB, Zhu YQ, Zhou ZG, Chen MS. Inflammation Prognostic Score and its Correlation with the Prognosis of Radiofrequency Ablation in Liver Cancer. *Guangdong Yixue* 2018; **33**: 2294-2299 [DOI: 10.13820/j.cnki.gdyx.20180809.014]
- 26 **Wang WW**, Zhang Y, Huang XB, You N, Zheng L, Li J. Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride-induced acute hepatic dysfunction. *World J Gastroenterol* 2017; **23**: 6983-6994 [PMID: 29097871 DOI: 10.3748/wjg.v23.i38.6983]
- 27 **Oikonomou T**, Papatheodoridis GV, Samarkos M, Goulis I, Cholongitas E. Clinical impact of microbiome in patients with decompensated cirrhosis. *World J Gastroenterol* 2018; **24**: 3813-3820 [PMID: 30228776 DOI: 10.3748/wjg.v24.i34.3813]
- 28 **Häussinger D**, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. *Gut* 2008; **57**: 1156-1165 [PMID: 18628377 DOI: 10.1136/gut.2007.122176]
- 29 **Milosevic I**, Vujovic A, Barac A, Djelic M, Korac M, Radovanovic Spurnic A, Gmizic I, Stevanovic O, Djordjevic V, Lekic N, Russo E, Amedei A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. *Int J Mol Sci* 2019; **20** [PMID: 30658519 DOI: 10.3390/ijms20020395]

- 30 **Zeng Y**, Chen S, Fu Y, Wu W, Chen T, Chen J, Yang B, Ou Q. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. *J Viral Hepat* 2020; **27**: 143-155 [PMID: [31600845](#) DOI: [10.1111/jvh.13216](#)]
- 31 **Ren S**, Wang C, Chen A, Lv W, Gao R. The Probiotic *Lactobacillus paracasei* Ameliorates Diarrhea Cause by *Escherichia coli* O(8) via Gut Microbiota Modulation(1). *Front Nutr* 2022; **9**: 878808 [PMID: [35662940](#) DOI: [10.3389/fnut.2022.878808](#)]
- 32 **Li P**, Ren Z, Zhou J, Zhao A, Wang S, Xun Y, Jiang H, Wang P, Yuan Q, Zhang Y. Effect of *Lacticaseibacillus paracasei* N1115 on Immunomodulatory and Gut Microbial Composition in Young Children: A Randomized, Placebo-Controlled Study. *Nutrients* 2023; **15** [PMID: [37111189](#) DOI: [10.3390/nu15081970](#)]
- 33 **Fukui H**. Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step. *J Clin Transl Hepatol* 2017; **5**: 249-260 [PMID: [28936406](#) DOI: [10.14218/JCTH.2017.00008](#)]
- 34 **Moratalla A**, Gómez-Hurtado I, Moya-Pérez Á, Zapater P, Peiró G, González-Navajas JM, Gómez Del Pulgar EM, Such J, Sanz Y, Francés R. *Bifidobacterium pseudocatenulatum* CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis. *Eur J Nutr* 2016; **55**: 197-206 [PMID: [25657013](#) DOI: [10.1007/s00394-015-0837-x](#)]
- 35 **Fukui H**. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. *World J Hepatol* 2015; **7**: 425-442 [PMID: [25848468](#) DOI: [10.4254/wjh.v7.i3.425](#)]
- 36 **Bajaj JS**, Sikaroodi M, Shamsaddini A, Henseler Z, Santiago-Rodriguez T, Acharya C, Fagan A, Hylemon PB, Fuchs M, Gavis E, Ward T, Knights D, Gillevet PM. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. *Gut* 2021; **70**: 1162-1173 [PMID: [32998876](#) DOI: [10.1136/gutjnl-2020-322470](#)]
- 37 **Albillos A**, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. *J Hepatol* 2020; **72**: 558-577 [PMID: [31622696](#) DOI: [10.1016/j.jhep.2019.10.003](#)]
- 38 **Famouri F**, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. *J Pediatr Gastroenterol Nutr* 2017; **64**: 413-417 [PMID: [28230607](#) DOI: [10.1097/MPG.0000000000001422](#)]
- 39 **Keitel V**, Reinehr R, Gatsios P, Rupprecht C, Görg B, Selbach O, Häussinger D, Kubitz R. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells. *Hepatology* 2007; **45**: 695-704 [PMID: [17326144](#) DOI: [10.1002/hep.21458](#)]
- 40 **Wahlström A**, Sayin SI, Marschall HU, Bäckhed F. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. *Cell Metab* 2016; **24**: 41-50 [PMID: [27320064](#) DOI: [10.1016/j.cmet.2016.05.005](#)]
- 41 **Quan M**, Xing HC. Intestinal flora research progress associated with chronic liver disease. *Zhongguo Ganzangbing Zazhi (Dianziban)* **11**: 26-30
- 42 **Qin N**, Yang F, Li A, Prifti E, Chen Y, Shao L, Guo J, Le Chatelier E, Yao J, Wu L, Zhou J, Ni S, Liu L, Pons N, Batto JM, Kennedy SP, Leonard P, Yuan C, Ding W, Hu X, Zheng B, Qian G, Xu W, Ehrlich SD, Zheng S, Li L. Alterations of the human gut microbiome in liver cirrhosis. *Nature* 2014; **513**: 59-64 [PMID: [25079328](#) DOI: [10.1038/nature13568](#)]
- 43 **Wang YX**, Li W, Cheng DY, Liu SA, Zhang S, Han M, Zhu M, Sun J, Xing HC. Characteristics of intestinal flora of patients with hepatitis B related decompensated cirrhosis. *Zhonghua Shiyian He Linchuang Ganranbing Zazhi (Dianziban)* 2019; **13**: 110-116



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: office@baishideng.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

